低分子肝素治疗AECOPD患者对内皮舒缩因子的影响被引量：3

Effect of low molecular weight heparin on endothelial compression factor in AECOPD patients

下载PDF

导出

摘要目的研究低分子肝素治疗AECOPD患者的临床疗效及对内皮舒缩因子的影响。方法将本院收治的67例AECOPD患者随机分成实验组35例,对照组32例,收集健康体检患者33例为健康组;给予对照组常规治疗方案,实验组在常规治疗的基础上加用低分子肝素治疗;记录并比较实验组与对照组治疗前后的肺功能FEV1%、FEV1/FVC%数据,抽取各组静脉血检测内皮素-1(ET-1)、前列环素(PGI2)及D-dimer的血清水平及治疗前后差异。结果实验组与对照组治疗后肺功能明显改善;实验组与对照组治疗前血清ET-1、D-dimer水平较健康组明显升高;实验组与对照组治疗后血清ET-1、D-dimer水平有所下降,且实验组下降水平更显著;实验组与对照组治疗前血清PGI2水平较健康组明显降低,经治疗后血清PGI2水平有所升高,且实验组升高水平更显著,差异有统计学意义(P <0. 01)。结论对AECOPD使用低分子肝素治疗有助于改善肺功能及血管内皮舒缩功能,有较好的临床疗效。 Objective To study the clinical effect of low molecular weight heparin on AECOPD and its effect on endothelium contraction factor. Methods 67 AECOPD patients were randomly divided into the experimental group （35 cases） and the control group （32 cases）. Another 33 healthy people were taken as the healthy control group. The control group received routine treatment. The experimental group was given routine treatment and low molecular weight heparin. The value of FEV1% and FEV1/FVC% of pulmonary function were recorded and compared between the experimental group and the control group before and after treatment. The levels of endothelin-1 （ ET-1 ） , prostacyclin （ PGI2 ） and D-dimer were also recorded. Results Their lung function improved significantly after treatment in both groups. The levels of ET-1 and D-dimer in the experimental group and the control group before treatment were significantly higher than those in the healthy control group. The levels of ET-1, D-dimer in the experimental group and the control group was significantly lower after treatment. The level of PGI2 in the experimental group and the control group before treatment was significantly lower than that in the healthy control group. After treatment, serum PGI2 level increased and the level of the experimental group increased more significantly （ P 〈 0. 01 ）. Conclusion Low molecular weight heparin can improve pulmonary function and vascular endothelium systolic and contractile function in treatment of AECOPD patients, and it has good clinical efficacy.

作者江庆周瑞清郑法德刘斌杨瑞青郝建 JIANG Qing;ZHOU Rui-qing;ZHENG Fa-de;LIU Bin;YANG Rui-qing;HAO Jian(Department of Respiratory and Critical Care Medicine,Fuyang People＇s Hospital,Fuyang,Anhui 236000,China)

机构地区阜阳市人民医院呼吸与危重症医学科南京军区杭州疗养院心肺康复医学中心

出处《临床肺科杂志》 2018年第11期2057-2059,共3页 Journal of Clinical Pulmonary Medicine

关键词低分子肝素慢性阻塞性肺疾病急性加重期内皮素-1 前列环素 D-DIMER low moleeular weight heparin AECOPD ET-1 PGI2 D-dimer

分类号 R563.9 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献5

1王兆钺.D二聚体临床应用的进展[J].血栓与止血学,2014,20(1):46-48. 被引量：45
2王诚,张杰良,李延玲,郑世良.低分子肝素对老年慢性阻塞性肺疾病急性加重期患者血浆内皮素的影响[J].潍坊医学院学报,2016,38(3):200-202. 被引量：3
3廖艺璇,陈亚红,米文君.慢性阻塞性肺疾病肺血管重塑的研究进展[J].生理科学进展,2016,47(4):295-299. 被引量：21
4刘嫄,胡欣,史爱欣.肺动脉高压新型靶向治疗药物的临床研究进展[J].中国药房,2017,28(32):4589-4592. 被引量：10
5颜平,宁宁,荆志成.前列环素及其类似物在肺动脉高压中的应用[J].世界临床药物,2014,35(6):332-337. 被引量：7

二级参考文献51

1Smith A,秦春常.哪些凝血标志物可以增加传统危险因素对冠心病和缺血性中风的预测价值?Caerphilly研究[J].中国分子心脏病学杂志,2005,5(6):821-821. 被引量：43
2孙传兴.临床疾病诊断依据治疗好转标准[M]第2版.北京:人民军医出版社,1998.357.
3Rubin LJ. Primary pulmonary hypertention[J]. N Engl J Med, 1997, 336(2) : 111-117.
4D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension, Results from a national prospective study[J]. Ann Intern Med, 1991, 115 (5) : 343-349.
5Jing ZC, Parikh K, PulidoT, et al. Efficacy and safety of oral treprostinilmonotherapy for the treatment of pulmonary arterial hypertension: a randomized controlled trial [J]. Circulation, 2013, 127 (5) : 624-633.
6McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial [J]. J AmCoil Cardiol, 2010, 55 (18) : 1915-1922.
7Vane J, Corin RE. Prostacyclin: a vascular mediator[J]. Eur J Vase Endovasc Surg, 2003, 26 (6) : 571-578.
8Barst RJ, Rubin L J, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostaeyclin) with conventional therapy for primary pulmonary hypertension [J]. N Engl J Med, 1996, 334(5): 296-301.
9McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy[J]. Circulation, 2002, 106 (12) : 1477-1482.
10Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: A randomized, controlled trial[J]. Ann Intern Med, 2000, 132 (6) : 425-434.